Literature DB >> 25485510

Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle.

Vanessa Oakes1, Weili Wang, Brittney Harrington, Won Jae Lee, Heather Beamish, Kee Ming Chia, Alex Pinder, Hidemasa Goto, Masaki Inagaki, Sandra Pavey, Brian Gabrielli.   

Abstract

Whereas many components regulating the progression from S phase through G2 phase into mitosis have been identified, the mechanism by which these components control this critical cell cycle progression is still not fully elucidated. Cyclin A/Cdk2 has been shown to regulate the timing of Cyclin B/Cdk1 activation and progression into mitosis although the mechanism by which this occurs is only poorly understood. Here we show that depletion of Cyclin A or inhibition of Cdk2 during late S/early G2 phase maintains the G2 phase arrest by reducing Cdh1 transcript and protein levels, thereby stabilizing Claspin and maintaining elevated levels of activated Chk1 which contributes to the G2 phase observed. Interestingly, the Cyclin A/Cdk2 regulated APC/C(Cdh1) activity is selective for only a subset of Cdh1 targets including Claspin. Thus, a normal role for Cyclin A/Cdk2 during early G2 phase is to increase the level of Cdh1 which destabilises Claspin which in turn down regulates Chk1 activation to allow progression into mitosis. This mechanism links S phase exit with G2 phase transit into mitosis, provides a novel insight into the roles of Cyclin A/Cdk2 in G2 phase progression, and identifies a novel role for APC/C(Cdh1) in late S/G2 phase cell cycle progression.

Entities:  

Keywords:  APC/C, anaphase promoting complex/cyclosome; Cdh1; Cdk, cyclin dependent kinase; Cdk2; Cdki, cyclin dependent kinase inhibitor; Chk1; Chk1, checkpoint kinase 1; Claspin; Cyclin A; G2 phase

Mesh:

Substances:

Year:  2014        PMID: 25485510      PMCID: PMC4615124          DOI: 10.4161/15384101.2014.949111

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  49 in total

1.  Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase.

Authors:  Alwin Krämer; Niels Mailand; Claudia Lukas; Randi G Syljuåsen; Christopher J Wilkinson; Erich A Nigg; Jiri Bartek; Jiri Lukas
Journal:  Nat Cell Biol       Date:  2004-08-15       Impact factor: 28.824

2.  A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress.

Authors:  K Brooks; V Oakes; B Edwards; M Ranall; P Leo; S Pavey; A Pinder; H Beamish; P Mukhopadhyay; D Lambie; B Gabrielli
Journal:  Oncogene       Date:  2012-03-05       Impact factor: 9.867

3.  Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.

Authors:  M Bessa; M K Saville; R J Watson
Journal:  Oncogene       Date:  2001-06-07       Impact factor: 9.867

4.  Nonperiodic activity of the human anaphase-promoting complex-Cdh1 ubiquitin ligase results in continuous DNA synthesis uncoupled from mitosis.

Authors:  C S Sorensen; C Lukas; E R Kramer; J M Peters; J Bartek; J Lukas
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  A conserved cyclin-binding domain determines functional interplay between anaphase-promoting complex-Cdh1 and cyclin A-Cdk2 during cell cycle progression.

Authors:  C S Sørensen; C Lukas; E R Kramer; J M Peters; J Bartek; J Lukas
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

6.  Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells.

Authors:  B G Gabrielli; C P De Souza; I D Tonks; J M Clark; N K Hayward; K A Ellem
Journal:  J Cell Sci       Date:  1996-05       Impact factor: 5.285

7.  The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties.

Authors:  M K Saville; R J Watson
Journal:  Oncogene       Date:  1998-11-26       Impact factor: 9.867

8.  Cyclin A/Cdk2 complexes regulate activation of Cdk1 and Cdc25 phosphatases in human cells.

Authors:  Jayashree Mitra; Greg H Enders
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

9.  Mammalian Cdh1/Fzr mediates its own degradation.

Authors:  Tamar Listovsky; Yifat S Oren; Yana Yudkovsky; Hiro M Mahbubani; Aryeh M Weiss; Mario Lebendiker; Michael Brandeis
Journal:  EMBO J       Date:  2004-03-18       Impact factor: 11.598

10.  The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.

Authors:  Maria Castedo; Jean-Luc Perfettini; Thomas Roumier; Kenichi Yakushijin; David Horne; René Medema; Guido Kroemer
Journal:  Oncogene       Date:  2004-05-27       Impact factor: 9.867

View more
  24 in total

1.  The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2.

Authors:  Tarryn Willmer; Jade Peres; Shaheen Mowla; Amaal Abrahams; Sharon Prince
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Degrading Claspin away with Cdh1 and Cyclin A.

Authors:  Andrew Burgess
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Phosphorylation of CDC25A on SER283 in late S/G2 by CDK/cyclin complexes accelerates mitotic entry.

Authors:  Laurent Mazzolini; Anaïs Broban; Carine Froment; Odile Burlet-Schiltz; Arnaud Besson; Stéphane Manenti; Christine Dozier
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

4.  Comparative analysis of transcriptomes revealed the molecular mechanism of development of Tricholoma matsutake at different stages of fruiting bodies.

Authors:  Xian Tang; Xiang Ding; Yi-Ling Hou
Journal:  Food Sci Biotechnol       Date:  2020-01-28       Impact factor: 2.391

5.  Posttranscriptional control of the replication stress response via TTP-mediated Claspin mRNA stabilization.

Authors:  Tae-Hee Lee; Ji Ye Choi; Jeong-Min Park; Tae-Hong Kang
Journal:  Oncogene       Date:  2020-02-21       Impact factor: 9.867

6.  [6]-Gingerol Suppresses Oral Cancer Cell Growth by Inducing the Activation of AMPK and Suppressing the AKT/mTOR Signaling Pathway.

Authors:  Haibo Zhang; Eungyung Kim; Junkoo Yi; Huang Hai; Hyeonjin Kim; Sijun Park; Su-Geun Lim; Si-Yong Kim; Soyoung Jang; Kirim Kim; Eun-Kyong Kim; Youngkyun Lee; Zaeyoung Ryoo; Myoungok Kim
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 7.  Insights into APC/C: from cellular function to diseases and therapeutics.

Authors:  Zhuan Zhou; Mingjing He; Anil A Shah; Yong Wan
Journal:  Cell Div       Date:  2016-07-13       Impact factor: 5.130

8.  RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.

Authors:  Mingming Liu; Zihao Qi; Bingzhi Liu; Yi Ren; Hanbin Li; Gong Yang; Qian Zhang
Journal:  Oncotarget       Date:  2015-09-22

9.  Analysis of DNA methylation in chondrocytes in rats with knee osteoarthritis.

Authors:  Xinxin Wang; Dezhi Tang; Peng Shen; Hao Xu; Hongfu Qiu; Tao Wu; Xiang Gao
Journal:  BMC Musculoskelet Disord       Date:  2017-08-31       Impact factor: 2.362

10.  A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.

Authors:  Ilaria Laurenzana; Antonella Caivano; Stefania Trino; Luciana De Luca; Francesco La Rocca; Vittorio Simeon; Cristina Tintori; Francesca D'Alessio; Antonella Teramo; Renato Zambello; Antonio Traficante; Maddalena Maietti; Gianpietro Semenzato; Silvia Schenone; Maurizio Botta; Pellegrino Musto; Luigi Del Vecchio
Journal:  Oncotarget       Date:  2016-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.